Celgene Corp.'s Istodax (romidepsin) got an accelerated nod, as expected, in peripheral T-cell lymphoma (PTCL) patients who have received at least one prior therapy, pitting it against Allos Therapeutics Inc.'s Folotyn (pralatrexate), a drug that suffered slower-than-expected sales despite being the first approved for PTCL.